Azithramycine
Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
Cross Reference
Introduction
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Azithramycine?
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (156)
- Clin. Infect. Dis. (64)
- J. Antimicrob. Chemother. (50)
- Others (435)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Azithramycine
PubChem Associated disorders and diseases
What pathways are associated with Azithramycine
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Azithramycine?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (66)
- J. Antimicrob. Chemother. (25)
- Clin. Infect. Dis. (13)
- Others (151)
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with Azithramycine?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Azithramycine?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with Azithramycine?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (44)
- J. Antimicrob. Chemother. (18)
- Clin. Infect. Dis. (10)
- Others (126)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Azithramycine?
Mouse Model
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
NCBI Entrez Crosslinks
All references with Azithramycine
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Stieger N et al. | Solution-mediated crystallization of amorphous azithromycin. | 2017 | Pharmazie | pmid:29441902 |
| Feng X and Liu J | A combination of irsogladine maleate and azithromycin exhibits addictive protective effects in LPS-induced human gingival epithelial cells. | 2017 | Pharmazie | pmid:29441859 |
| Okayasu S et al. | A survey on diarrhea and convenience of intake associated with a single-dose extended release formulation of azithromycin. | 2011 | Pharmazie | pmid:21553656 |
| Xue-Min Z et al. | Determination of azithromycin in human plasma by LC-MS-MS and its pharmacokinetics. | 2007 | Pharmazie | pmid:17484278 |
| Togami K et al. | Transport characteristics of clarithromycin, azithromycin and telithromycin, antibiotics applied for treatment of respiratory infections, in Calu-3 cell monolayers as model lung epithelial cells. | 2012 | Pharmazie | pmid:22764569 |
| Najib MM et al. | Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia. | 2000 | Pharmacotherapy | pmid:10772376 |
| Pollak PT and Slayter KL | Reduced serum theophylline concentrations after discontinuation of azithromycin: evidence for an unusual interaction. | 1997 Jul-Aug | Pharmacotherapy | pmid:9250566 |
| Bizjak ED et al. | Intravenous azithromycin-induced ototoxicity. | 1999 | Pharmacotherapy | pmid:10030778 |
| Toltzis P | Comparison of amoxicillin with alternative agents for the treatment of acute otitis media in children. | 2005 | Pharmacotherapy | pmid:16305281 |
| Shrader SP et al. | Azithromycin and warfarin interaction. | 2004 | Pharmacotherapy | pmid:15303459 |
| Gaylor AS and Reilly JC | Therapy with macrolides in patients with cystic fibrosis. | 2002 | Pharmacotherapy | pmid:11837560 |
| Beckey NP et al. | Retrospective evaluation of a potential interaction between azithromycine and warfarin in patients stabilized on warfarin. | 2000 | Pharmacotherapy | pmid:10999497 |
| Drew RH and Gallis HA | Azithromycin--spectrum of activity, pharmacokinetics, and clinical applications. | 1992 | Pharmacotherapy | pmid:1319048 |
| Page RL et al. | Possible interaction between intravenous azithromycin and oral cyclosporine. | 2001 | Pharmacotherapy | pmid:11714218 |
| Ernst EJ et al. | Comparison of the serum and intracellular pharmacokinetics of azithromycin in healthy and diabetic volunteers. | 2000 | Pharmacotherapy | pmid:10853621 |
| Prescott WA and Johnson CE | Antiinflammatory therapies for cystic fibrosis: past, present, and future. | 2005 | Pharmacotherapy | pmid:15977917 |
| Eschenauer G et al. | Azithromycin-warfarin interaction: are we fishing with a red herring? | 2005 | Pharmacotherapy | pmid:15977924 |
| Woodruff AE et al. | Azithromycin-Induced, Biopsy-Proven Acute Interstitial Nephritis in an Adult Successfully Treated with Low-Dose Corticosteroids. | 2015 | Pharmacotherapy | pmid:26598102 |
| Stevens RC et al. | Pharmacokinetics of azithromycin after single- and multiple-doses in children. | 1997 Sep-Oct | Pharmacotherapy | pmid:9324176 |
| Destache CJ et al. | Microbiologic effect of bovine cerebrospinal fluid and azithromycin against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. | 1997 Sep-Oct | Pharmacotherapy | pmid:9324186 |
| LaPlante KL et al. | Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting. | 2008 | Pharmacotherapy | pmid:18154478 |
| Tilelli JA et al. | Life-threatening bradyarrhythmia after massive azithromycin overdose. | 2006 | Pharmacotherapy | pmid:16506357 |
| Petitta A et al. | Economic evaluation of three methods of treating urogenital chlamydial infections in the emergency department. | 1999 | Pharmacotherapy | pmid:10331829 |
| Foster DR and Milan NL | Potential interaction between azithromycin and warfarin. | 1999 | Pharmacotherapy | pmid:10417043 |
| McCall KL et al. | Determination of the lack of a drug interaction between azithromycin and warfarin. | 2004 | Pharmacotherapy | pmid:14998219 |
| Poachanukoon O et al. | Macrolides attenuate phorbol ester-induced tumor necrosis factor-α and mucin production from human airway epithelial cells. | 2014 | Pharmacology | pmid:24556631 |
| Parnham MJ et al. | Azithromycin: mechanisms of action and their relevance for clinical applications. | 2014 | Pharmacol. Ther. | pmid:24631273 |
| Di Paolo A et al. | Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily. | 2002 | Pharmacol. Res. | pmid:12457629 |
| Baschiera F et al. | Improved tonsillar disposition of azithromycin following a 3-day oral treatment with 20 mg kg(-1) in paediatric patients. | 2002 | Pharmacol. Res. | pmid:12208127 |
| Matijašić M et al. | Fluorescently labeled macrolides as a tool for monitoring cellular and tissue distribution of azithromycin. | 2012 | Pharmacol. Res. | pmid:22749903 |
| Banjanac M et al. | Anti-inflammatory mechanism of action of azithromycin in LPS-stimulated J774A.1 cells. | 2012 | Pharmacol. Res. | pmid:22766077 |
| Graziani F et al. | Clinical evaluation of piroxicam-FDDF and azithromycin in the prevention of complications associated with impacted lower third molar extraction. | 2005 | Pharmacol. Res. | pmid:16140544 |
| Bachmann K et al. | Influence of a 3-day regimen of azithromycin on the disposition kinetics of cyclosporine A in stable renal transplant patients. | 2003 | Pharmacol. Res. | pmid:12742010 |
| Marjanović N et al. | Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro. | 2011 | Pharmacol. Res. | pmid:21315154 |
| Szałek E et al. | Sunitinib in combination with clarithromycin or azithromycin - is there a risk of interaction or not? | 2012 | Pharmacol Rep | pmid:23406766 |
| He XJ et al. | Influence of ABCB1 gene polymorphisms on the pharmacokinetics of azithromycin among healthy Chinese Han ethnic subjects. | 2009 Sep-Oct | Pharmacol Rep | pmid:19904007 |
| Fohner AE et al. | PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. | 2017 | Pharmacogenet. Genomics | pmid:28146011 |
| Quach C et al. | Effectiveness of amoxicillin, azithromycin, cefprozil and clarithromycin in the treatment of acute otitis media in children: a population-based study. | 2005 | Pharmacoepidemiol Drug Saf | pmid:15386697 |
| Palcevski G et al. | Antibiotic use profile at paediatric clinics in two transitional countries. | 2004 | Pharmacoepidemiol Drug Saf | pmid:15072118 |
| Goldstein LH et al. | Azithromycin is not associated with QT prolongation in hospitalized patients with community-acquired pneumonia. | 2015 | Pharmacoepidemiol Drug Saf | pmid:26238864 |
| Bérard A et al. | Use of macrolides during pregnancy and the risk of birth defects: a population-based study. | 2015 | Pharmacoepidemiol Drug Saf | pmid:26513406 |
| Lea AP and Lamb HM | Azithromycin. A pharmacoeconomic review of its use as a single-dose regimen in the treatment of uncomplicated urogenital Chlamydia trachomatis infections in women. | 1997 | Pharmacoeconomics | pmid:10174326 |
| Zhong M et al. | Azithromycin cationic non-lecithoid nano/microparticles improve bioavailability and targeting efficiency. | 2014 | Pharm. Res. | pmid:25208873 |
| Wang Z and Meenach SA | Synthesis and Characterization of Nanocomposite Microparticles (nCmP) for the Treatment of Cystic Fibrosis-Related Infections. | 2016 | Pharm. Res. | pmid:27091030 |
| Curatolo W | Interdisciplinary science and the design of a single-dose antibiotic therapy. | 2011 | Pharm. Res. | pmid:21311957 |
| Curatolo W et al. | Effects of food on a gastrically degraded drug: azithromycin fast-dissolving gelatin capsules and HPMC capsules. | 2011 | Pharm. Res. | pmid:21331473 |
| Berquand A et al. | Interaction of the macrolide antibiotic azithromycin with lipid bilayers: effect on membrane organization, fluidity, and permeability. | 2005 | Pharm. Res. | pmid:15835753 |
| Chanteux H et al. | Cell handling, membrane-binding properties, and membrane-penetration modeling approaches of pivampicillin and phthalimidomethylampicillin, two basic esters of ampicillin, in comparison with chloroquine and azithromycin. | 2003 | Pharm. Res. | pmid:12739771 |
| Evans LA et al. | Predicting injection site muscle damage. III: Evaluation of intramuscular formulations in the L6 cell model. | 1996 | Pharm. Res. | pmid:8899856 |
| Curatolo W et al. | Mechanistic study of the azithromycin dosage-form-dependent food effect. | 2010 | Pharm. Res. | pmid:20372991 |